Luigi Manenti

1.3k citations
20 papers · 886 indexed · 1 hit paper · h-index 10

Luigi Manenti

18 papers receiving 876 citations

Hit Papers

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 A...257202120262022202450100150200250

Peers

Luigi Manenti
Comparison fields: 5 of 81
  • Oncology 470
  • Immunology 284
  • Physiology 54
  • Cancer Research 171
  • Reproductive Medicine 65
Replace Behrouz Zand with:
Behrouz Zand United States
Evangeline Mose United States
Chenfei Zhou China
Gengtai Ye China
Chongbiao Huang China
Ruben Bill Switzerland
Massimo Pancione Italy
Samuel W. Brady United States
Catherine Richon France
Karen Morrison United Kingdom
Luigi Manenti relative to Behrouz Zand United States Behrouz Zand's profile →
Citations per field
00.5×4.2×
Behrouz Zand · 1×
Citations per year

Countries citing papers authored by Luigi Manenti

Since Specialization
Citations

This map shows the geographic impact of Luigi Manenti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi Manenti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi Manenti more than expected).

Fields of papers citing papers by Luigi Manenti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luigi Manenti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi Manenti. The network helps show where Luigi Manenti may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Luigi Manenti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Luigi Manenti Line = papers co-authored together Luigi Manenti links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20241
2 20230
3 20231
4 20232
5 20231
6 202250
7 20225
8
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumorsbreakdown →
2021257
9 201932
10 20192
11 201837
12 20168
13 201322
14 20131
15 20124
16 201167
17 200525
18 200446
19
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
2003273
20
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
200352

About Luigi Manenti

Luigi Manenti is a scholar working on Physiology, Oncology, Neurology, Reproductive Medicine and Pulmonary and Respiratory Medicine, having authored 20 papers that have together received 886 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Colorectal Cancer Treatments and Studies (4 papers), Peptidase Inhibition and Analysis (3 papers), CAR-T cell therapy research (2 papers), Ovarian cancer diagnosis and treatment (2 papers), Adenosine and Purinergic Signaling (2 papers), Barrier Structure and Function Studies (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). The work is most often cited by research in Oncology (470 citations), Immunology (284 citations), Physiology (54 citations), Cancer Research (171 citations) and Reproductive Medicine (65 citations). Luigi Manenti has collaborated with scholars based in United States, Italy and Switzerland. Frequent co-authors include Raffaella Giavazzi, Angela Garofalo, Dorina Belotti, Sergio Marchini, Giulia Taraboletti, Giuseppe Curigliano, Toshihiko Doi, Armando Santoro, Tyler A. Longmire and John Sarantopoulos. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics and Journal of the American Society of Nephrology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026